After grabbing 4.5 million shares, the institutional investor is now in possession of 4.5 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 14.06% having worth around $119.61 million. Moreover, Baker Bros. Advisors LP increased its share by 2.11 million to have a control over 2.11 million shares. And Renaissance Technologies LLC raised its holdings to 0.31 million shares by acquiring 0.93 million shares or 2.89% of the stake.
Altimmune Inc. (ALT) concluded trading on 08/26/20 at a closing price of $18.42, with 3.32 million shares of worth about $61.08 million changed hands on the day. Weekly performance of the stock remained negative as price took a plunge of -24.60% during that period and on Wednesday the price saw a loss of about -14.60%. Currently the company’s common shares owned by public are about 32.90M shares, out of which, 23.89M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 3 analysts are covering the ALT stock and their offered price forecasts bring an average price target of $55.00. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $80.00 and could fall to a lowest price of $35.00. Analysts also issued an outlook of 2.00 for the Altimmune Inc. stock for next 12 months. However, touching the estimated high of $80.00 would mean a gain of 76.97% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 26 times over the past 12 months. They bought 2,878,221 shares in 15 of the transactions. In 11 selling transactions, insiders dumped 240,081 shares.
Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and Invesco Health Care Fund are the top 3 mutual funds which are holding stakes in Altimmune Inc. Vanguard Total Stock Market Index is currently holding 0.53 million shares of worth totaling $14.21 million. The company recently came buying 0.14 million shares which brought its stake up to 1.67% of the company’s outstanding shares. Vanguard Extended Market Index Fu sold 326.0 shares, after which its hold over company’s outstanding shares shrunk to 0.57%, leaving 0.18 million shares with the mutual fund that have a worth of about $4.89 million. Invesco Health Care Fund, after buying 0.17 million shares, have now control over 0.52% of the stake in the company. It holds 0.17 million shares of worth $4.4 million.
Altimmune Inc. (NASDAQ: ALT) started trading at $21.42, below -$0.15 from concluding price of the previous day. However, the stock finished the trading on the day at a closing price of $18.42, or with a loss of -14.60%. Stock saw a price change of -24.60% in past 5 days and over the past one month there was a price change of -21.95%. Year-to-date (YTD), ALT shares are showing a performance of 874.60% which increased to 839.80% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.51 but also hit the highest price of $35.10 during that period. While comparing its average daily trading volume of 4.70 million shares, we see that about 3.32 million changed hands on the day. The stock is currently trading -26.64% below its 20-day simple moving average (SMA20), while that difference is down -10.38% for SMA50 and it goes to 148.21% higher than SMA200.
VHCP Management LLC acquired 4.5 million shares of Altimmune Inc. having value of about $119.61 million. Altimmune Inc. (NASDAQ: ALT) currently have 32.90M outstanding shares and institutions hold larger chunk of about 40.60% of that. Holding of mutual funds in the company is about 3.55% while other institutional holders and individual stake holders have control over 38.09% and 20.55% of the stake respectively.
The stock has a current market capitalization of $657.23M and its 3Y-monthly beta is at 2.16. It has posted earnings per share of -$2.21 in the same period. It has Quick Ratio of 17.90 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALT, volatility over the week remained 12.56% while standing at 11.45% over the month.
Analysts are in expectations that Altimmune Inc. (ALT) stock would likely to be making an EPS of -$0.8 in the current quarter, while forecast for next quarter ESPS is -$1.61 and it is $2.47 for next year. For the current quarter EPS, analysts have given the company a lowest target -$1.16 which is -$0.45 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.73 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 89.50% while it is estimated to increase by 174.80% in next year.
Analysts at 3 brokerage firms have issued recommendations for the Altimmune Inc. (ALT)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.00. Out of those 3 Wall Street analysts, 3 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Evercore ISI on August 14, 2020 offering an Outperform rating for the stock and assigned a target price of to it. Coverage by Piper Sandler stated Altimmune Inc. (ALT) stock as an Overweight in their note to investors on July 31, 2020, suggesting a price target of $80 for the stock. On July 28, 2020, JMP Securities Initiated their recommendations, while on February 24, 2020, ROTH Capital Resumed their ratings for the stock with a price target of $13. Stock get a Buy rating from ROTH Capital on July 19, 2019.